Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes

1Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235-71. doi: 10.1146/annurev-immunol-031210-101324 Vesely MD Kershaw MH Schreiber RD Smyth MJ Natural innate and adaptive immunity to cancer Annu Rev Immunol 2011 29 235 71 10.1146/annurev-immunol-031210-10132421219185Open DOISearch in Google Scholar

2Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331: 1565-70. doi: 10.1126/science.1203486 Schreiber RD Old LJ Smyth MJ Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion Science 2011 331 1565 70 10.1126/science.120348621436444Open DOISearch in Google Scholar

3Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 1676-80. doi: 10.1056/nejm198812223192527 Rosenberg SA Packard BS Aebersold PM Solomon D Topalian SL Toy ST et al Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma N Engl J Med 1988 319 1676 80 10.1056/nejm1988122231925273264384Open DOISearch in Google Scholar

4Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature 2017; 545: 423-31. doi: 10.1038/nature22395 Sadelain M Rivière I Riddell S Therapeutic T cell engineering Nature 2017 545 423 31 10.1038/nature22395563294928541315Open DOISearch in Google Scholar

5Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509-18. doi: 10.1056/NEJMoa1215134 Grupp SA Kalos M Barrett D Aplenc R Porter DL Rheingold SR et al Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 2013 368 1509 18 10.1056/NEJMoa1215134405844023527958Open DOISearch in Google Scholar

6Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018; 378: 439-48. doi: 10.1056/nejmoa1709866 Maude SL Laetsch TW Buechner J Rives S Boyer M Bittencourt H et al Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia N Engl J Med 2018 378 439 48 10.1056/nejmoa1709866599639129385370Open DOISearch in Google Scholar

7Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385: 517-28. doi: 10.1016/S0140-6736(14)61403-3 Lee DW Kochenderfer JN Stetler-Stevenson M Cui YK Delbrook C Feldman SA et al T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Lancet 2015 385 517 28 10.1016/S0140-6736(14)61403-3706535925319501Open DOISearch in Google Scholar

8Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 2017; 28: 2545-54. doi: 10.1056/NEJMoa1708566 Schuster SJ Svoboda J Chong EA Nasta SD Mato AR Anak Ö et al Chimeric antigen receptor T cells in refractory B-cell lymphomas N Engl J Med 2017 28 2545 54 10.1056/NEJMoa1708566578856629226764Open DOISearch in Google Scholar

9Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 2016; 30: 492-500. doi: 10.1038/leu.2015.247 Sommermeyer D Hudecek M Kosasih PL Gogishvili T Maloney DG Turtle CJ et al Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo Leukemia 2016 30 492 500 10.1038/leu.2015.247474609826369987Open DOISearch in Google Scholar

10Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118: 4817-28. doi: 10.1182/blood-2011-04-348540 Brentjens RJ Rivière I Park JH Davila ML Wang X Stefanski J et al Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Blood 2011 118 4817 28 10.1182/blood-2011-04-348540320829321849486Open DOISearch in Google Scholar

11Porter DL, Levine BL, Kalos M, Bagg A, June CH, Levine BL, et al. Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-33. doi: 10.1056/nejmoa1103849 Porter DL Levine BL Kalos M Bagg A June CH Levine BL et al Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia N Engl J Med 2011 365 725 33 10.1056/nejmoa1103849Open DOISearch in Google Scholar

12Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017; 377: 2531-44. doi: 10.1056/nejmoa1707447 Neelapu SS Locke FL Bartlett NL Lekakis LJ Miklos DB Jacobson CA et al Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma N Engl J Med 2017 377 2531 44 10.1056/nejmoa1707447Open DOISearch in Google Scholar

13Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019; 380: 45-56. doi: 10.1056/nejmoa1804980 Schuster SJ Bishop MR Tam CS Waller EK Borchmann P McGuirk JP et al Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma N Engl J Med 2019 380 45 56 10.1056/nejmoa180498030501490Open DOISearch in Google Scholar

14Abramson JS, McGree B, Sarah Noyes N, Sean Plummer B, Curtis Wong B, Chen YB, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med 2017; 377: 783-4. doi: 10.1056/NEJMc1704610 Abramson JS McGree B Sarah Noyes N Sean Plummer B Curtis Wong B Chen YB et al Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma N Engl J Med 2017 377 783 4 10.1056/NEJMc170461028834486Open DOISearch in Google Scholar

15Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73. doi: 10.1126/scitranslmed.3002842 Kalos M Levine BL Porter DL Katz S Grupp SA Bagg A et al T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci Transl Med 2011 3 95ra73 10.1126/scitranslmed.3002842339309621832238Open DOISearch in Google Scholar

16Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116: 4099-102. doi: 10.1182/blood-2010-04-281931 Kochenderfer JN Wilson WH Janik JE Dudley ME Stetler-Stevenson M Feldman SA et al Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 2010 116 4099 102 10.1182/blood-2010-04-281931299361720668228Open DOISearch in Google Scholar

17Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol 2017; 15: 47-62. doi: 10.1038/nrclinonc.2017.148 Neelapu SS Tummala S Kebriaei P Wierda W Gutierrez C Locke FL et al Chimeric antigen receptor T-cell therapy – assessment and management of toxicities Nat Rev Clin Oncol 2017 15 47 62 10.1038/nrclinonc.2017.148673340328925994Open DOISearch in Google Scholar

18Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 2019; 34: 45-55. doi: 10.1016/j.blre.2018.11.002 Brudno JN Kochenderfer JN Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management Blood Rev 2019 34 45 55 10.1016/j.blre.2018.11.002662869730528964Open DOISearch in Google Scholar

19Liu E, Marin D, Banerjee P, MacApinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 2020; 382: 545-53. doi: 10.1056/nejmoa1910607 Liu E Marin D Banerjee P MacApinlac HA Thompson P Basar R et al Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors N Engl J Med 2020 382 545 53 10.1056/nejmoa1910607710124232023374Open DOISearch in Google Scholar

20Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol 2020; 38: 947-53. doi: 10.1038/s41587-020-0462-y Klichinsky M Ruella M Shestova O Lu XM Best A Zeeman M et al Human chimeric antigen receptor macrophages for cancer immunotherapy Nat Biotechnol 2020 38 947 53 10.1038/s41587-020-0462-y788363232361713Open DOISearch in Google Scholar

21Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 2016; 353: 179-84. doi: 10.1126/science.aaf6756 Ellebrecht CT Bhoj VG Nace A Choi EJ Mao X Cho MJ et al Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease Science 2016 353 179 84 10.1126/science.aaf6756534351327365313Open DOISearch in Google Scholar

22Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 2022; 28: 2124-32. doi: 10.1038/s41591-022-02017-5 Mackensen A Müller F Mougiakakos D Böltz S Wilhelm A Aigner M et al Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus Nat Med 2022 28 2124 32 10.1038/s41591-022-02017-536109639Open DOISearch in Google Scholar

23Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 2021; 385: 567-9. doi: 10.1056/nejmc2107725 Mougiakakos D Krönke G Völkl S Kretschmann S Aigner M Kharboutli S et al CD19-Targeted CAR T cells in refractory systemic lupus erythematosus N Engl J Med 2021 385 567 9 10.1056/nejmc2107725Open DOISearch in Google Scholar

24Maldini CR, Gayout K, Leibman RS, Dopkin DL, Mills JP, Shan X, et al. HIV-resistant and HIV-specific CAR-modified CD4+ T cells mitigate HIV disease progression and confer CD4+ T cell help in vivo. Mol Ther 2020; 28: 1-15. doi: 10.1016/j.ymthe.2020.05.012 Maldini CR Gayout K Leibman RS Dopkin DL Mills JP Shan X et al HIV-resistant and HIV-specific CAR-modified CD4+ T cells mitigate HIV disease progression and confer CD4+ T cell help in vivo Mol Ther 2020 28 1 15 10.1016/j.ymthe.2020.05.012733575232454027Open DOISearch in Google Scholar

25Maldini CR, Claiborne DT, Okawa K, Chen T, Dopkin DL, Shan X, et al. Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo. Nat Med 2020; 26: 1776-87. doi: 10.1038/s41591-020-1039-5 Maldini CR Claiborne DT Okawa K Chen T Dopkin DL Shan X et al Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo Nat Med 2020 26 1776 87 10.1038/s41591-020-1039-5942208632868878Open DOISearch in Google Scholar

26Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 2020; 583: 127-32. doi: 10.1038/s41586-020-2403-9 Amor C Feucht J Leibold J Ho YJ Zhu C Alonso-Curbelo D et al Senolytic CAR T cells reverse senescence-associated pathologies Nature 2020 583 127 32 10.1038/s41586-020-2403-9758356032555459Open DOISearch in Google Scholar

27Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, et al. Targeting cardiac fibrosis with engineered T cells. Nature 2019; 573: 430-3. doi: 10.1038/s41586-019-1546-z Aghajanian H Kimura T Rurik JG Hancock AS Leibowitz MS Li L et al Targeting cardiac fibrosis with engineered T cells Nature 2019 573 430 3 10.1038/s41586-019-1546-z675296431511695Open DOISearch in Google Scholar

28Kalos M, June CH. Adoptive T Cell Transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013; 39: 49-60. doi: 10.1016/j. immuni.2013.07.002 Kalos M June CH Adoptive T Cell Transfer for cancer immunotherapy in the era of synthetic biology Immunity 2013 39 49 60 10.1016/j.immuni.2013.07.002380903823890063Open DOISearch in Google Scholar

29June CH, O ’connor RS, Kawalekar OU, Ghassemi S, Milone MC, O’Connor RS, et al. CAR T cell immunotherapy for human cancer. Science 2018; 1365: 1361-5. doi: 10.1126/science.aar6711 June CH ’connor RS O Kawalekar OU Ghassemi S Milone MC O’Connor RS et al CAR T cell immunotherapy for human cancer Science 2018 1365 1361 5 10.1126/science.aar671129567707Open DOISearch in Google Scholar

30Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, et al. Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 1987; 149: 960-8. doi: 10.1016/0006-291X(87)90502-X Kuwana Y Asakura Y Utsunomiya N Nakanishi M Arata Y Itoh S et al Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions Biochem Biophys Res Commun 1987 149 960 8 10.1016/0006-291X(87)90502-X3122749Open DOISearch in Google Scholar

31Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993; 90: 720-4. doi: 10.1073/pnas.90.2.720 Eshhar Z Waks T Gross G Schindler DG Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors Proc Natl Acad Sci U S A 1993 90 720 4 10.1073/pnas.90.2.720457378421711Open DOISearch in Google Scholar

32Brocker T, Karjalainen K. Signals through T cell receptor-ζ chain alone are insufficient to prime resting T lymphocytes. J Exp Med 1995; 181: 1653-9. doi: 10.1084/jem.181.5.1653 Brocker T Karjalainen K Signals through T cell receptor-ζ chain alone are insufficient to prime resting T lymphocytes J Exp Med 1995 181 1653 9 10.1084/jem.181.5.165321920067722445Open DOISearch in Google Scholar

33Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, et al Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med 2019; 25: 1408-14. doi: 10.1038/s41591-019-0549-5 Ghorashian S Kramer AM Onuoha S Wright G Bartram J Richardson R et al Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR Nat Med 2019 25 1408 14 10.1038/s41591-019-0549-531477906Open DOISearch in Google Scholar

34Singh N, Frey N V., Engels B, Barrett DM, Shestova O, Ravikumar P, et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat Med 2021; 27: 842-50. doi: 10.1038/s41591-021-01326-5 Singh N Frey N V. Engels B Barrett DM Shestova O Ravikumar P et al Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells Nat Med 2021 27 842 50 10.1038/s41591-021-01326-5845103233888899Open DOISearch in Google Scholar

35Posey AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 2016; 44: 1444-54. doi: 10.1016/j.immuni.2016.05.014 Posey AD Schwab RD Boesteanu AC Steentoft C Mandel U Engels B et al Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma Immunity 2016 44 1444 54 10.1016/j.immuni.2016.05.014535866727332733Open DOISearch in Google Scholar

36Harris DT, Kranz DM. Adoptive T Cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol Sci 2015; 37: 220-30. doi: 10.1016/j.tips.2015.11.004 Harris DT Kranz DM Adoptive T Cell therapies: a comparison of T cell receptors and chimeric antigen receptors Trends Pharmacol Sci 2015 37 220 30 10.1016/j.tips.2015.11.004476445426705086Open DOISearch in Google Scholar

37Bashor CJ, Hilton IB, Bandukwala H, Smith DM, Veiseh O. Engineering the next generation of cell-based therapeutics. Nat Rev Drug Discov 2022; 21: 655-75. doi: 10.1038/s41573-022-00476-6 Bashor CJ Hilton IB Bandukwala H Smith DM Veiseh O Engineering the next generation of cell-based therapeutics Nat Rev Drug Discov 2022 21 655 75 10.1038/s41573-022-00476-6914967435637318Open DOISearch in Google Scholar

38Mullard A. FDA approves second BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov 2022; 21: 249. doi: 10.1038/d41573-022-00048-8 Mullard A FDA approves second BCMA-targeted CAR-T cell therapy Nat Rev Drug Discov 2022 21 249 10.1038/d41573-022-00048-835277677Open DOISearch in Google Scholar

39MacKay M, Afshinnekoo E, Rub J, Hassan C, Khunte M, Baskaran N, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol 2020; 38: 233-44. doi: 10.1038/s41587-019-0329-2 MacKay M Afshinnekoo E Rub J Hassan C Khunte M Baskaran N et al The therapeutic landscape for cells engineered with chimeric antigen receptors Nat Biotechnol 2020 38 233 44 10.1038/s41587-019-0329-231907405Open DOISearch in Google Scholar

40Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res 2016; 27: 38-58. doi: 10.1038/cr.2016.154 Johnson LA June CH Driving gene-engineered T cell immunotherapy of cancer Cell Res 2016 27 38 58 10.1038/cr.2016.154522323428025979Open DOISearch in Google Scholar

41Elazar A, Chandler NJ, Davey AS, Weinstein JY, Nguyen J V., Trenker R, et al. De novo-designed transmembrane domains tune engineered receptor functions. Elife 2022; 11: 1-29. doi: 10.7554/eLife.75660 Elazar A Chandler NJ Davey AS Weinstein JY Nguyen J V Trenker R et al De novo-designed transmembrane domains tune engineered receptor functions Elife 2022 11 1 29 10.7554/eLife.75660906822335506657Open DOISearch in Google Scholar

42Muller YD, Nguyen DP, Ferreira LMR, Ho P, Raffin C, Valencia RVB, et al. The CD28-transmembrane domain mediates chimeric antigen receptor heter-odimerization with CD28. Front Immunol 2021; 12: 639818. doi: 10.3389/fimmu.2021.639818 Muller YD Nguyen DP Ferreira LMR Ho P Raffin C Valencia RVB et al The CD28-transmembrane domain mediates chimeric antigen receptor heter-odimerization with CD28 Front Immunol 2021 12 639818 10.3389/fimmu.2021.639818802195533833759Open DOISearch in Google Scholar

43Kershaw MH, Westwood J a, Parker LL, Wang G, Eshhar Z, Mavroukakis S a, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12: 6106-15. doi: 10.1158/1078-0432.CCR-06-1183 Kershaw MH Westwood J a Parker LL Wang G Eshhar Z Mavroukakis S a et al A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Clin Cancer Res 2006 12 6106 15 10.1158/1078-0432.CCR-06-1183215435117062687Open DOISearch in Google Scholar

44Krause A, Guo HF, Latouche JB, Tan C, Cheung NK V., Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 1998; 188: 619-26. doi: 10.1084/jem.188.4.619 Krause A Guo HF Latouche JB Tan C Cheung NK V Sadelain M Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes J Exp Med 1998 188 619 26 10.1084/jem.188.4.61922133619705944Open DOISearch in Google Scholar

45Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol 2002; 20: 70-5. doi: 10.1038/nbt0102-70 Maher J Brentjens RJ Gunset G Rivière I Sadelain M Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor Nat Biotechnol 2002 20 70 5 10.1038/nbt0102-7011753365Open DOISearch in Google Scholar

46Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule. J Immunol 2001; 167: 6123-31. doi: 10.4049/jimmunol.167.11.6123 Hombach A Wieczarkowiecz A Marquardt T Heuser C Usai L Pohl C et al Tumor-specific T cell activation by recombinant immunoreceptors: CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule J Immunol 2001 167 6123 31 10.4049/jimmunol.167.11.612311714771Open DOISearch in Google Scholar

47Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T Cells. Immunity 2016; 44: 380-90. doi: 10.1016/j.immuni.2016.01.021 Kawalekar OU O’Connor RS Fraietta JA Guo L McGettigan SE Posey AD et al Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T Cells Immunity 2016 44 380 90 10.1016/j.immuni.2016.01.02126885860Open DOISearch in Google Scholar

48Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med 2022; 28: 2145-54. doi: 10.1038/s41591-022-01969-y Bachy E Le Gouill S Di Blasi R Sesques P Manson G Cartron G et al A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma Nat Med 2022 28 2145 54 10.1038/s41591-022-01969-y955632336138152Open DOISearch in Google Scholar

49Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 2012; 119: 696-706. doi: 10.1182/blood-2011-03-344275 Song DG Ye Q Poussin M Harms GM Figini M Powell DJ CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo Blood 2012 119 696 706 10.1182/blood-2011-03-34427522117050Open DOISearch in Google Scholar

50Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, et al. ICOS-based chimeric antigen receptors program bipolar TH 17/ TH1 cells. Blood 2014; 124: 1070-80. doi: 10.1182/blood-2013-10-535245 Guedan S Chen X Madar A Carpenito C McGettigan SE Frigault MJ et al ICOS-based chimeric antigen receptors program bipolar TH 17/ TH1 cells Blood 2014 124 1070 80 10.1182/blood-2013-10-535245413348224986688Open DOISearch in Google Scholar

51Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells. Oncoimmunology 2012; 1: 458-66. doi: 10.4161/onci.19855 Hombach AA Heiders J Foppe M Chmielewski M Abken H OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells Oncoimmunology 2012 1 458 66 10.4161/onci.19855338291222754764Open DOISearch in Google Scholar

52Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell Non-Hodgkin’s lymphomas. Mol Ther 2018; 26: 2727-37. doi: 10.1016/j.ymthe.2018.09.009 Ramos CA Rouce R Robertson CS Reyna A Narala N Vyas G et al In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell Non-Hodgkin’s lymphomas Mol Ther 2018 26 2727 37 10.1016/j.ymthe.2018.09.009627748430309819Open DOISearch in Google Scholar

53Wijewarnasuriya D, Bebernitz C, Lopez AV, Rafiq S, Brentjens RJ. Excessive costimulation leads to dysfunction of adoptively transferred T cells. Cancer Immunol Res 2020; 18: 732-42. doi: 10.1158/2326-6066.CIR-19-0908 Wijewarnasuriya D Bebernitz C Lopez AV Rafiq S Brentjens RJ Excessive costimulation leads to dysfunction of adoptively transferred T cells Cancer Immunol Res 2020 18 732 42 10.1158/2326-6066.CIR-19-0908726981532213625Open DOISearch in Google Scholar

54Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MKA, et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 2022; 602: 503-9. doi: 10.1038/s41586-021-04390-6 Melenhorst JJ Chen GM Wang M Porter DL Chen C Collins MKA et al Decade-long leukaemia remissions with persistence of CD4+ CAR T cells Nature 2022 602 503 9 10.1038/s41586-021-04390-6916691635110735Open DOISearch in Google Scholar

55Gordon KS, Kyung T, Perez CR, Holec P V., Ramos A, Zhang AQ, et al. Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains. Nat Biomed Eng 2022; 6: 855-66. doi: 10.1038/s41551-022-00896-0 Gordon KS Kyung T Perez CR Holec P V. Ramos A Zhang AQ et al Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains Nat Biomed Eng 2022 6 855 66 10.1038/s41551-022-00896-0938944235710755Open DOISearch in Google Scholar

56Love PE, Hayes SM. ITAM-mediated signaling by the T-cell antigen receptor. Cold Spring Harb Perspect Biol 2010; 2: 1-11. doi: 10.1101/cshperspect. a002485 Love PE Hayes SM ITAM-mediated signaling by the T-cell antigen receptor Cold Spring Harb Perspect Biol 2010 2 1 11 10.1101/cshperspect.a002485286951820516133Open DOISearch in Google Scholar

57Wu W, Zhou Q, Masubuchi T, Shi X, Li H, Xu X, et al. Multiple signaling roles of CD3ε and its application in CAR-T cell therapy. Cell 2020; 182: 855-871. e23. doi: 10.1016/j.cell.2020.07.018 Wu W Zhou Q Masubuchi T Shi X Li H Xu X et al Multiple signaling roles of CD3ε and its application in CAR-T cell therapy Cell 2020 182 855 871 e23 10.1016/j.cell.2020.07.01832730808Open DOISearch in Google Scholar

58Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med 2019; 25: 82-8. doi: 10.1038/s41591-018-0290-5 Feucht J Sun J Eyquem J Ho YJ Zhao Z Leibold J et al Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency Nat Med 2019 25 82 8 10.1038/s41591-018-0290-5653206930559421Open DOISearch in Google Scholar

59Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat Med 2022; 28: 345-52. doi: 10.1038/s41591-021-01621-1 Mansilla-Soto J Eyquem J Haubner S Hamieh M Feucht J Paillon N et al HLA-independent T cell receptors for targeting tumors with low antigen density Nat Med 2022 28 345 52 10.1038/s41591-021-01621-1946964735027758Open DOISearch in Google Scholar

60Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res 2015; 21: 2278-88. doi: 10.1158/1078-0432. CCR-14-2085 Zhang L Morgan RA Beane JD Zheng Z Dudley ME Kassim SH et al Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma Clin Cancer Res 2015 21 2278 88 10.1158/1078-0432.CCR-14-2085443381925695689Open DOISearch in Google Scholar

61Hu B, Ren J, Luo Y, Scholler J, Zhao Y, June CH, et al. CAR T cells secreting IL18 augment antitumor immunity and increase T cell proliferation and costimulation. Cell Rep 2017; 20: 3025-33. doi: 10.1016/j.celrep.2017.09.002 Hu B Ren J Luo Y Scholler J Zhao Y June CH et al CAR T cells secreting IL18 augment antitumor immunity and increase T cell proliferation and costimulation Cell Rep 2017 20 3025 33 10.1016/j.celrep.2017.09.002600276228954221Open DOISearch in Google Scholar

62Kunert A, Chmielewski M, Wijers R, Berrevoets C, Abken H, Debets R. Intratumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors. Oncoimmunology 2017; 7: 1-12. doi: 10.1080/2162402X.2017.1378842 Kunert A Chmielewski M Wijers R Berrevoets C Abken H Debets R Intratumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors Oncoimmunology 2017 7 1 12 10.1080/2162402X.2017.1378842573957129296541Open DOISearch in Google Scholar

63Chmielewski M, Abken H. CAR T cells releasing IL-18 convert to T-Bet high FoxO1 low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep 2017; 21: 3205-19. doi: 10.1016/j.celrep.2017.11.063 Chmielewski M Abken H CAR T cells releasing IL-18 convert to T-Bet high FoxO1 low effectors that exhibit augmented activity against advanced solid tumors Cell Rep 2017 21 3205 19 10.1016/j.celrep.2017.11.06329241547Open DOISearch in Google Scholar

64Zimmermann K, Kuehle J, Dragon AC, Galla M, Kloth C, Rudek LS, et al. Design and characterization of an “all-in-one” lentiviral vector system combining constitutive anti-gd2 car expression and inducible cytokines. Cancers 2020; 12: 1-22. doi: 10.3390/cancers12020375 Zimmermann K Kuehle J Dragon AC Galla M Kloth C Rudek LS et al Design and characterization of an “all-in-one” lentiviral vector system combining constitutive anti-gd2 car expression and inducible cytokines Cancers 2020 12 1 22 10.3390/cancers12020375707261732041222Open DOISearch in Google Scholar

65Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 2018; 36: 847-56. doi: 10.1038/nbt.4195 Rafiq S Yeku OO Jackson HJ Purdon TJ van Leeuwen DG Drakes DJ et al Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo Nat Biotechnol 2018 36 847 56 10.1038/nbt.4195612693930102295Open DOISearch in Google Scholar

66Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, et al. Checkpoint blockade reverses anergy in IL-13Rα2 humanized scFv-based CAR T cells to treat murine and canine gliomas. Mol Ther Oncolytics 2018; 11: 20-38. doi: 10.1016/j.omto.2018.08.002 Yin Y Boesteanu AC Binder ZA Xu C Reid RA Rodriguez JL et al Checkpoint blockade reverses anergy in IL-13Rα2 humanized scFv-based CAR T cells to treat murine and canine gliomas Mol Ther Oncolytics 2018 11 20 38 10.1016/j.omto.2018.08.002617484530306125Open DOISearch in Google Scholar

67Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez A V., Curran KJ, Daniyan AF, et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 2019; 35: 473-88. doi: 10.1016/j.ccell.2019.02.006 Kuhn NF Purdon TJ van Leeuwen DG Lopez A V. Curran KJ Daniyan AF et al CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response Cancer Cell 2019 35 473 88 10.1016/j.ccell.2019.02.006642821930889381Open DOISearch in Google Scholar

68Yamamoto TN, Lee P-HH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, et al. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J Clin Invest 2019; 129: 1551-65. doi: 10.1172/JCI121491 Yamamoto TN Lee P-HH Vodnala SK Gurusamy D Kishton RJ Yu Z et al T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy J Clin Invest 2019 129 1551 65 10.1172/JCI121491643688030694219Open DOISearch in Google Scholar

69Oda SK, Anderson KG, Ravikumar P, Bonson P, Garcia NM, Jenkins CM, et al. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy. J Exp Med 2020; 217: 1-16. doi: 10.1084/jem.20191166 Oda SK Anderson KG Ravikumar P Bonson P Garcia NM Jenkins CM et al A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy J Exp Med 2020 217 1 16 10.1084/jem.20191166795373332860705Open DOISearch in Google Scholar

70Jin C, Ma J, Ramachandran M, Yu D, Essand M. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nat Biomed Eng 2022; 6: 830-41. doi: 10.1038/s41551-022-00875-5 Jin C Ma J Ramachandran M Yu D Essand M CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers Nat Biomed Eng 2022 6 830 41 10.1038/s41551-022-00875-5928893435379957Open DOISearch in Google Scholar

71Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 2022; 28: 724-34. doi: 10.1038/s41591-022-01726-1 Narayan V Barber-Rotenberg JS Jung IY Lacey SF Rech AJ Davis MM et al PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial Nat Med 2022 28 724 34 10.1038/s41591-022-01726-135314843Open DOISearch in Google Scholar

72Roth TL, Li PJ, Blaeschke F, Nies JF, Apathy R, Mowery C, et al. Pooled knockin targeting for genome engineering of cellular immunotherapies. Cell 2020; 181: 728-744.e21. doi: 10.1016/j.cell.2020.03.039 Roth TL Li PJ Blaeschke F Nies JF Apathy R Mowery C et al Pooled knockin targeting for genome engineering of cellular immunotherapies Cell 2020 181 728 744 e21 10.1016/j.cell.2020.03.039721952832302591Open DOISearch in Google Scholar

73Roybal KT, Williams JZ, Morsut L, Walker WJ, Mcnally KA, Lim WA. Engineering T cells with customized therapeutic article engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 2016; 167: 419-32. doi: 10.1016/j.cell.2016.09.011 Roybal KT Williams JZ Morsut L Walker WJ Mcnally KA Lim WA Engineering T cells with customized therapeutic article engineering T cells with customized therapeutic response programs using synthetic notch receptors Cell 2016 167 419 32 10.1016/j.cell.2016.09.011507253327693353Open DOISearch in Google Scholar

74Rodriguez-garcia A, Lynn RC, Poussin M, Eiva MA, Shaw LC, Connor RSO, et al. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat Commun 2021; 12: 877. doi: 10.1038/s41467-021-20893-2 Rodriguez-garcia A Lynn RC Poussin M Eiva MA Shaw LC Connor RSO et al CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy Nat Commun 2021 12 877 10.1038/s41467-021-20893-2787305733563975Open DOISearch in Google Scholar

75Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 2018; 24: 563-71. doi: 10.1038/s41591-018-0010-1 Fraietta JA Lacey SF Orlando EJ Pruteanu-Malinici I Gohil M Lundh S et al Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia Nat Med 2018 24 563 71 10.1038/s41591-018-0010-1611761329713085Open DOISearch in Google Scholar

76Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 2021; 184: 6081-6100.e26. doi: 10.1016/j.cell.2021.11.016 Good CR Aznar MA Kuramitsu S Samareh P Agarwal S Donahue G et al An NK-like CAR T cell transition in CAR T cell dysfunction Cell 2021 184 6081 6100e26 10.1016/j.cell.2021.11.016882716734861191Open DOISearch in Google Scholar

77Weber EW, Parker KR, Sotillo E, Lynn RC, Anbunathan H, Lattin J, et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 2021; 372: eaba1786. doi: 10.1126/science. aba 1786 Weber EW Parker KR Sotillo E Lynn RC Anbunathan H Lattin J et al Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling Science 2021 372 eaba1786 10.1126/science.aba 1786Open DOISearch in Google Scholar

78Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 2019; 576: 293-300. doi: 10.1038/s41586-019-1805-z Lynn RC Weber EW Sotillo E Gennert D Xu P Good Z et al c-Jun overexpression in CAR T cells induces exhaustion resistance Nature 2019 576 293 300 10.1038/s41586-019-1805-z694432931802004Open DOISearch in Google Scholar

79Seo H, González-Avalos E, Zhang W, Ramchandani P, Yang C, Lio CWJ, et al BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat Immunol 2021; 22: 983-95. doi: 10.1038/s41590-021-00964-8 Seo H González-Avalos E Zhang W Ramchandani P Yang C Lio CWJ et al BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells Nat Immunol 2021 22 983 95 10.1038/s41590-021-00964-8831910934282330Open DOISearch in Google Scholar

80Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 2020; 26: 1878-87. doi: 10.1038/s41591-020-1061-7 Deng Q Han G Puebla-Osorio N Ma MCJ Strati P Chasen B et al Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas Nat Med 2020 26 1878 87 10.1038/s41591-020-1061-7844690933020644Open DOISearch in Google Scholar

81Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 2018; 36: 346-51. doi: 10.1038/nbt.4086 Adachi K Kano Y Nagai T Okuyama N Sakoda Y Tamada K IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor Nat Biotechnol 2018 36 346 51 10.1038/nbt.408629505028Open DOISearch in Google Scholar

82Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov 2017; 7: 1238-47. doi: 10.1158/2159-8290.CD-17-0538 Shum T Omer B Tashiro H Kruse RL Wagner DL Parikh K et al Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells Cancer Discov 2017 7 1238 47 10.1158/2159-8290.CD-17-0538566983028830878Open DOISearch in Google Scholar

83Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res 2019; 7: 759-72. doi: 10.1158/2326-6066.CIR-18-0466 Alizadeh D Wong RA Yang X Wang D Pecoraro JR Kuo CF et al IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype Cancer Immunol Res 2019 7 759 72 10.1158/2326-6066.CIR-18-0466668756130890531Open DOISearch in Google Scholar

84Kalbasi A, Siurala M, Su LL, Tariveranmoshabad M, Picton LK, Ravikumar P, et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature 2022; 607: 360-5. doi: 10.1038/s41586-022-04801-2 Kalbasi A Siurala M Su LL Tariveranmoshabad M Picton LK Ravikumar P et al Potentiating adoptive cell therapy using synthetic IL-9 receptors Nature 2022 607 360 5 10.1038/s41586-022-04801-2928331335676488Open DOISearch in Google Scholar

85Legut M, Gajic Z, Guarino M, Daniloski Z, Rahman JA, Xue X, et al. A genome-scale screen for synthetic drivers of T cell proliferation. Nature 2022; 603: 728-35. doi: 10.1038/s41586-022-04494-7 Legut M Gajic Z Guarino M Daniloski Z Rahman JA Xue X et al A genome-scale screen for synthetic drivers of T cell proliferation Nature 2022 603 728 35 10.1038/s41586-022-04494-7990843735296855Open DOISearch in Google Scholar

86Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18: 843-51. doi: 10.1038/mt.2010.24 Morgan RA Yang JC Kitano M Dudley ME Laurencot CM Rosenberg SA Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol Ther 2010 18 843 51 10.1038/mt.2010.24286253420179677Open DOISearch in Google Scholar

87Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 2018; 173: 1439-1453.e19. doi: 10.1016/j.cell.2018.05.013 Kim MY Yu KR Kenderian SS Ruella M Chen S Shin TH et al Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia Cell 2018 173 1439 1453 e19 10.1016/j.cell.2018.05.013600342529856956Open DOISearch in Google Scholar

88Qazi MA, Vora P, Venugopal C, Sidhu SS, Moffat J, Swanton C, et al. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann Oncol 2017; 28: 1448-56. doi: 10.1093/annonc/mdx169 Qazi MA Vora P Venugopal C Sidhu SS Moffat J Swanton C et al Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma Ann Oncol 2017 28 1448 56 10.1093/annonc/mdx16928407030Open DOISearch in Google Scholar

89Ruella M, Maus M V. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J 2016; 14: 357-62. doi: 10.1016/j.csbj.2016.09.003 Ruella M Maus M V Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies Comput Struct Biotechnol J 2016 14 357 62 10.1016/j.csbj.2016.09.003506107427761200Open DOISearch in Google Scholar

90Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S, et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med 2021; 27: 1797-805. doi: 10.1038/s41591-021-01497-1 Cordoba S Onuoha S Thomas S Pignataro DS Hough R Ghorashian S et al CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial Nat Med 2021 27 1797 805 10.1038/s41591-021-01497-1851664834642489Open DOISearch in Google Scholar

91Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 2018; 24: 20-8. doi: 10.1038/nm.4441 Fry TJ Shah NN Orentas RJ Stetler-Stevenson M Yuan CM Ramakrishna S et al CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy Nat Med 2018 24 20 8 10.1038/nm.4441577464229155426Open DOISearch in Google Scholar

92Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 2021; 27: 1419-31. doi: 10.1038/s41591-021-01436-0 Spiegel JY Patel S Muffly L Hossain NM Oak J Baird JH et al CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial Nat Med 2021 27 1419 31 10.1038/s41591-021-01436-0836350534312556Open DOISearch in Google Scholar

93Minutolo NG, Sharma P, Poussin M, Shaw LC, Brown DP, Hollander EE, et al. Quantitative control of gene-engineered T-cell activity through the covalent attachment of targeting ligands to a universal immune receptor. J Am Chem Soc 2020; 142: 6554-68. doi: 10.1021/jacs.9b11622 Minutolo NG Sharma P Poussin M Shaw LC Brown DP Hollander EE et al Quantitative control of gene-engineered T-cell activity through the covalent attachment of targeting ligands to a universal immune receptor J Am Chem Soc 2020 142 6554 68 10.1021/jacs.9b11622730617632191035Open DOISearch in Google Scholar

94Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 2018; 173: 1426-1438. e11. doi: 10.1016/j.cell.2018.03.038 Cho JH Collins JJ Wong WW Universal chimeric antigen receptors for multiplexed and logical control of T cell responses Cell 2018 173 1426 1438 e11 10.1016/j.cell.2018.03.038598415829706540Open DOISearch in Google Scholar

95Tran E, Robbins PF, Lu Y-C, Prickett TD, Gartner JJ, Jia L, et al T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 2016; 375: 2255-62. doi: 10.1056/NEJMoa1609279 Tran E Robbins PF Lu Y-C Prickett TD Gartner JJ Jia L et al T-cell transfer therapy targeting mutant KRAS in cancer N Engl J Med 2016 375 2255 62 10.1056/NEJMoa1609279517882727959684Open DOISearch in Google Scholar

96Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, et al. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med 2018; 215: 141-57. doi: 10.1084/jem.20171046 Chheda ZS Kohanbash G Okada K Jahan N Sidney J Pecoraro M et al Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy J Exp Med 2018 215 141 57 10.1084/jem.20171046574885629203539Open DOISearch in Google Scholar

97Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, Shih Y-P, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med 2022; 386: 2112-9. doi: 10.1056/nejmoa2119662 Leidner R Sanjuan Silva N Huang H Sprott D Zheng C Shih Y-P et al Neoantigen T-cell receptor gene therapy in pancreatic cancer N Engl J Med 2022 386 2112 9 10.1056/nejmoa2119662953175535648703Open DOISearch in Google Scholar

98Bear AS, Blanchard T, Cesare J, Ford MJ, Richman LP, Xu C, et al. Biochemical and functional characterization of mutant KRAS epitopes validates this on-coprotein for immunological targeting. Nat Commun 2021; 12: 1-16. doi: 10.1038/s41467-021-24562-2 Bear AS Blanchard T Cesare J Ford MJ Richman LP Xu C et al Biochemical and functional characterization of mutant KRAS epitopes validates this on-coprotein for immunological targeting Nat Commun 2021 12 1 16 10.1038/s41467-021-24562-2828537234272369Open DOISearch in Google Scholar

99Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, et al. Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. Nature 2021; 599: 477-84. doi: 10.1038/s41586-021-04061-6 Yarmarkovich M Marshall QF Warrington JM Premaratne R Farrel A Groff D et al Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs Nature 2021 599 477 84 10.1038/s41586-021-04061-6859900534732890Open DOISearch in Google Scholar

100Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 2018; 24: 1499-503. doi: 10.1038/s41591-018-0201-9 Ruella M Xu J Barrett DM Fraietta JA Reich TJ Ambrose DE et al Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell Nat Med 2018 24 1499 503 10.1038/s41591-018-0201-9651198830275568Open DOISearch in Google Scholar

101Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M, et al. Rapid manufacturing of non-activated potent CAR T cells. Nat Biomed Eng 2022; 6: 118-28. doi: 10.1038/s41551-021-00842-6 Ghassemi S Durgin JS Nunez-Cruz S Patel J Leferovich J Pinzone M et al Rapid manufacturing of non-activated potent CAR T cells Nat Biomed Eng 2022 6 118 28 10.1038/s41551-021-00842-6886036035190680Open DOISearch in Google Scholar

102Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016; 126: 2123-38. doi: 10.1172/JCI85309 Turtle CJ Hanafi LA Berger C Gooley TA Cherian S Hudecek M et al CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients J Clin Invest 2016 126 2123 38 10.1172/JCI85309488715927111235Open DOISearch in Google Scholar

103Arcangeli S, Bove C, Mezzanotte C, Camisa B, Falcone L, Manfredi F, et al. CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Invest 2022; 132: e150807. doi: 10.1172/JCI150807 Arcangeli S Bove C Mezzanotte C Camisa B Falcone L Manfredi F et al CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome J Clin Invest 2022 132 e150807 10.1172/JCI150807919752935503659Open DOISearch in Google Scholar

104Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 2020; 19: 185-99. doi: 10.1038/s41573-019-0051-2 Depil S Duchateau P Grupp SA Mufti G Poirot L . ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges Nat Rev Drug Discov 2020 19 185 99 10.1038/s41573-019-0051-231900462Open DOISearch in Google Scholar

105Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med 2017; 9: 1-9. doi: 10.1126/scitranslmed. aaj2013 Qasim W Zhan H Samarasinghe S Adams S Amrolia P Stafford S et al Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells Sci Transl Med 2017 9 1 9 10.1126/scitranslmed.aaj201328123068Open DOISearch in Google Scholar

106Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med 2020; 26: 732-40. doi: 10.1038/s41591-020-0840-5 Lu Y Xue J Deng T Zhou X Yu K Deng L et al Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer Nat Med 2020 26 732 40 10.1038/s41591-020-0840-532341578Open DOISearch in Google Scholar

107Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science 2020; 367: 1-12. doi: 10.1126/science.aba7365 Stadtmauer EA Fraietta JA Davis MM Cohen AD Weber KL Lancaster E et al CRISPR-engineered T cells in patients with refractory cancer Science 2020 367 1 12 10.1126/science.aba736532029687Open DOISearch in Google Scholar

108Eyquem J, Mansilla-Soto J, Giavridis T, Van Der Stegen SJC, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 2017; 543: 113-7. doi: 10.1038/nature21405 Eyquem J Mansilla-Soto J Giavridis T Van Der Stegen SJC Hamieh M Cunanan KM et al Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection Nature 2017 543 113 7 10.1038/nature21405555861428225754Open DOISearch in Google Scholar

109Dai X, Park JJ, Du Y, Kim HR, Wang G, Errami Y, et al. One-step generation of modular CAR-T cells with AAV-Cpf1. Nat Methods 2019; 16: 247-54. doi: 10.1038/s41592-019-0329-7 Dai X Park JJ Du Y Kim HR Wang G Errami Y et al One-step generation of modular CAR-T cells with AAV-Cpf1 Nat Methods 2019 16 247 54 10.1038/s41592-019-0329-7651974630804551Open DOISearch in Google Scholar

110Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 2018; 559: 405-9. doi: 10.1038/s41586-018-0326-5 Roth TL Puig-Saus C Yu R Shifrut E Carnevale J Li PJ et al Reprogramming human T cell function and specificity with non-viral genome targeting Nature 2018 559 405 9 10.1038/s41586-018-0326-5623941729995861Open DOISearch in Google Scholar

111Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature 2022; 609: 369-74. doi: 10.1038/s41586-022-05140-y Zhang J Hu Y Yang J Li W Zhang M Wang Q et al Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL Nature 2022 609 369 74 10.1038/s41586-022-05140-y945229636045296Open DOISearch in Google Scholar

112Rurik JG, Tombácz I, Yadegari A, Fernández POM, Shewale S V, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science 2022; 96: 91-6. doi: 10.1126/science.abm0594 Rurik JG Tombácz I Yadegari A Fernández POM Shewale S V Li L et al CAR T cells produced in vivo to treat cardiac injury Science 2022 96 91 6 10.1126/science.abm0594998361134990237Open DOISearch in Google Scholar

113June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med 2017; 23: 540-7. doi: 10.1038/nm.4321 June CH Warshauer JT Bluestone JA Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med 2017 23 540 7 10.1038/nm.432128475571Open DOISearch in Google Scholar

114Singh N, Hofmann TJ, Gershenson Z, Levine BL, Grupp SA, Teachey DT, et al. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy 2017; 19: 867-80. doi: 10.1016/j. jcyt.2017.04.001 Singh N Hofmann TJ Gershenson Z Levine BL Grupp SA Teachey DT et al Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function Cytotherapy 2017 19 867 80 10.1016/j.jcyt.2017.04.001667648528506444Open DOISearch in Google Scholar

115Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 2020; 183: 126-142.e17. doi: 10.1016/j.cell.2020.08.022 Parker KR Migliorini D Perkey E Yost KE Bhaduri A Bagga P et al Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies Cell 2020 183 126 142 e17 10.1016/j.cell.2020.08.022764076332961131Open DOISearch in Google Scholar

116Wu C-Y, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 2015; 350: aab4077. doi: 10.1126/science.aab4077 Wu C-Y Roybal KT Puchner EM Onuffer J Lim WA Remote control of therapeutic T cells through a small molecule-gated chimeric receptor Science 2015 350 aab4077 10.1126/science.aab4077472162926405231Open DOISearch in Google Scholar

117Juillerat A, Marechal A, Filhol JM, Valton J, Duclert A, Poirot L, et al. Design of chimeric antigen receptors with integrated controllable transient functions. Sci Rep 2016; 6: 1-7. doi: 10.1038/srep18950 Juillerat A Marechal A Filhol JM Valton J Duclert A Poirot L et al Design of chimeric antigen receptors with integrated controllable transient functions Sci Rep 2016 6 1 7 10.1038/srep18950470744026750734Open DOISearch in Google Scholar

118Giordano-Attianese G, Gainza P, Gray-Gaillard E, Cribioli E, Shui S, Kim S, et al. A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. Nat Biotechnol 2020; 38: 426-32. doi: 10.1038/s41587-019-0403-9 Giordano-Attianese G Gainza P Gray-Gaillard E Cribioli E Shui S Kim S et al A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy Nat Biotechnol 2020 38 426 32 10.1038/s41587-019-0403-932015549Open DOISearch in Google Scholar

119Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010; 24: 1160-70. doi: 10.1038/leu.2010.75 Hoyos V Savoldo B Quintarelli C Mahendravada A Zhang M Vera J et al Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety Leukemia 2010 24 1160 70 10.1038/leu.2010.75288814820428207Open DOISearch in Google Scholar

120Paszkiewicz PJ, Fräßle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest 2016; 126: 4262-72. doi: 10.1172/JCI84813 Paszkiewicz PJ Fräßle SP Srivastava S Sommermeyer D Hudecek M Drexler I et al Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia J Clin Invest 2016 126 4262 72 10.1172/JCI84813509689927760047Open DOISearch in Google Scholar

121Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 2016; 164: 1-10. doi: 10.1016/j.cell.2016.01.011 Roybal KT Rupp LJ Morsut L Walker WJ McNally KA Park JS et al Precision tumor recognition by T cells with combinatorial antigen-sensing circuits Cell 2016 164 1 10 10.1016/j.cell.2016.01.011475290226830879Open DOISearch in Google Scholar

122Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 2015; 350: 1387-90. doi: 10.1126/science.aad1253 Tran E Ahmadzadeh M Lu YC Gros A Turcotte S Robbins PF et al Immunogenicity of somatic mutations in human gastrointestinal cancers Science 2015 350 1387 90 10.1126/science.aad1253744589226516200Open DOISearch in Google Scholar

123Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 2018; 1: 724-30. doi: 10.1038/s41591-018-0040-8 Zacharakis N Chinnasamy H Black M Xu H Lu YC Zheng Z et al Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer Nat Med 2018 1 724 30 10.1038/s41591-018-0040-8634847929867227Open DOISearch in Google Scholar